[Myocardial remodeling in patients with chronic heart failure and implanted cardiac contractility modulators]

A A Safiullina1, T M Uskach1,2, S V Dobrovolskaya1

  • 1National Medical Research Center of Cardiology.

Terapevticheskii Arkhiv
|October 26, 2022
PubMed

Insights

Cardiac contractility modulation (CCM) therapy positively impacts left ventricular remodeling and myocardial function in chronic heart failure (HF) patients with atrial fibrillation (AF). Echocardiography effectively monitors these improvements.

Area of Science:

  • Cardiology
  • Biomedical Engineering

Context:

  • Chronic heart failure (HF) with atrial fibrillation (AF) presents complex challenges in cardiac function and remodeling.
  • Assessing therapeutic interventions for HF requires robust imaging and functional analysis.

Purpose:

  • To investigate the impact of cardiac contractility modulation (CCM) on reverse remodeling and myocardial function in patients with chronic HF.
  • To evaluate the effectiveness of CCM therapy using echocardiography (EchoCG).

Summary:

  • A 12-month study analyzed 40 patients with chronic HF and AF undergoing CCM therapy.
  • Standard EchoCG parameters and left ventricular (LV) myocardial work were assessed.
  • Results showed a statistically significant positive effect of CCM on LV remodeling and myocardial work.

Impact:

  • Transthoracic echocardiography is crucial for evaluating HF treatment efficacy, including non-pharmacological methods like CCM.
  • Assessing LV myocardial function in HF patients with CCM devices offers a promising research avenue.
Abstract

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
27
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.7K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
31
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
19
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
487
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
37